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OBJECTIVE—Subjects with diabetes experience an increased
risk of myocardial infarction and cardiac failure compared with
nondiabetic age-matched individuals. The receptor for advanced
glycation end products (RAGE) is upregulated in diabetic tissues.
In this study, we tested the hypothesis that RAGE affected
ischemia/reperfusion (I/R) injury in the diabetic myocardium. In
diabetic rat hearts, expression of RAGE and its ligands was
enhanced and localized particularly to both endothelial cells and
mononuclear phagocytes.
RESEARCH DESIGN AND METHODS—To speciﬁcally dis-
sect the impact of RAGE, homozygous RAGE-null mice and
transgenic (Tg) mice expressing cytoplasmic domain-deleted
RAGE (DN RAGE), in which RAGE-dependent signal transduc-
tion was deﬁcient in endothelial cells or mononuclear phago-
cytes, were rendered diabetic with streptozotocin. Isolated
perfused hearts were subjected to I/R.
RESULTS—Diabetic RAGE-null mice were signiﬁcantly pro-
tected from the adverse impact of I/R injury in the heart, as
indicated by decreased release of LDH and lower glycoxidation
products carboxymethyl-lysine (CML) and pentosidine, im-
proved functional recovery, and increased ATP. In diabetic Tg
mice expressing DN RAGE in endothelial cells or mononuclear
phagocytes, markers of ischemic injury and CML were signiﬁ-
cantly reduced, and levels of ATP were increased in heart tissue
compared with littermate diabetic controls. Furthermore, key
markers of apoptosis, caspase-3 activity and cytochrome c
release, were reduced in the hearts of diabetic RAGE-modiﬁed
mice compared with wild-type diabetic littermates in I/R.
CONCLUSIONS—These ﬁndings demonstrate novel and key
roles for RAGE in I/R injury in the diabetic heart. Diabetes 57:
1941–1951, 2008
C
ardiac complications remain a leading cause of
morbidity and mortality in subjects with diabe-
tes (1–3). Although many factors contribute to
depressed cardiac function in diabetes, innate
disturbances within the diabetic heart contribute impor-
tantly to progressive dysfunction, which often leads to
irreversible failure and death (3). Alterations in substrate
metabolism and increased levels of oxygen free radicals
have been observed in diabetic tissues. Inﬂammatory
cytokines may exert direct negative inotropic effects on
cardiac myocytes and contribute to aberrant remodeling in
the failed heart (4–8). The pathophysiology of diabetes-
associated cardiac complications is complex and involves
a host of factors linked to metabolic and immune/inﬂam-
matory cell activation.
The accumulation of late-stage glycoxidation adducts of
proteins, termed advanced glycation end products (AGEs),
occurs in diabetic tissues. AGEs modify long-lived mole-
cules in the blood vessel wall and structural tissues of the
heart considerably earlier than symptomatic cardiac dys-
function occurs (9). A major way in which AGEs exert
their cellular effects is by ligation of the multiligand
receptor for AGE (RAGE) (10–13).
We tested the role of RAGE in rodent models of type 1
diabetes, and we show that pharmacological blockade of
ligand-RAGE interaction or genetic modulation of RAGE
suppresses ischemia/reperfusion (I/R) injury in the iso-
lated perfused heart, at least in part secondary to critical
contributions evoked from RAGE-expressing endothelial
cells and mononuclear phagocytes in the diabetic heart.
RESEARCH DESIGN AND METHODS
All animal studies were performed with the approval of the Institutional
Animal Care and Use Committee of Columbia University and conform with the
Guide for the Care and Use of Laboratory Animals published by the National
Institutes of Health. Male diabetic Bio Bred (BB/W) rats, a model of type 1
diabetes (Biomedical Models, Worcester, MA) (14,15), were used. Rats
became diabetic between 69 and 80 days of age and were entered into study
at diagnosis of hyperglycemia. Age-matched nondiabetic BB/W rats were
controls. Diabetic rats were maintained on human insulin (3–5 units/dose)
(Humulin; Eli Lilly, Indianapolis, IN) twice daily. Insulin was discontinued 12 h
before isolated heart perfusion studies. Rats were killed after 2 weeks of
established diabetes. Murine soluble RAGE (sRAGE; 500 g/day) or equal
volumes of its diluent, PBS, were administered by intraperitoneal route
beginning immediately at the diagnosis of hyperglycemia (serum glucose
250 mg/dl) and continued for 14 days. sRAGE was prepared in a baculovirus
expression system, and the material was puriﬁed and devoid of contaminating
lipopolysaccharide (16).
Male BALB/c or C57BL/6 mice (The Jackson Laboratories, Bar Harbor, ME)
were rendered diabetic by 55 mg/kg i.p. streptozotocin (STZ) per day in fresh
citrate buffer (0.05 mol/l; pH 4.5) for 5 consecutive days. Mice displaying
serum glucose 250 mg/dl were considered diabetic. Control (nondiabetic)
animals received citrate buffer (16).
Homozygous RAGE-null mice and transgenic mice. Homozygous RAGE-
null mice (RAGE-KO) (17–19) were backcrossed 10 generations into C57BL/6
before study. Male RAGE-KO and littermate mice were used. In other studies,
two sets of transgenic mice were prepared to express signal transduction–
deﬁcient RAGE, or dominant-negative (DN) RAGE (11,12,18) in endothelial
cells (driven by the preproendothelin-1 [PPET] promoter; 20) or cells of
mononuclear phagocyte lineage (driven by the macrophage scavenger recep-
tor type A [MSR] promoter; 21,22). Transgenic (Tg) DN MSR RAGE and Tg DN
PPET RAGE mice were prepared and characterized as previously described
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study. Littermates not expressing the transgene were used as controls.
Western blotting. Left ventricles were retrieved and subjected to SDS-
PAGE/Western blotting using 1 g/ml anti-RAGE IgG (16); 0.25 g/ml anti-
inducible nitric oxide (NO) synthase (iNOS) IgG (Santa Cruz Biotechnology);
anti–cytochrome c IgG (Santa Cruz Biotechnology); or anti-glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) IgG (Cayman). After probing with the
primary antibodies, membranes were stripped of bound immunoglobulins and
reprobed with anti–-actin IgG (Sigma-Aldrich, St. Louis, MO). All antibodies
were used according to the manufacturer’s instructions. Analysis of band
density was performed using Image Quant/Molecular Dynamics software
(Foster City, CA). Results are reported as relative units based on the ratio of
test antibody densitometry units/-actin densitometry units.
Immunohistochemistry. Hearts were retrieved, and sections were prepared
for immunohistochemistry. The following antibodies were used: anti-RAGE
IgG (16), anti-AGE IgG (16), anti-S100/calgranulin IgG (12), and anti-nitroty-
rosine IgG (Upstate, Lake Placid, NY). To localize cell-speciﬁc expression of
RAGE, additional antibodies were used: anti-Mac 3 IgG (Pharmingen, San
Diego, CA) and anti-CD31 IgG (Pharmingen). Immunostaining with nonim-
mune IgGs of the relevant species were negative.
Levels of total nitrite and nitrate and cGMP. Hearts were retrieved and
rapidly snap-frozen in liquid nitrogen after I/R. Lysates were prepared and
levels of total nitrite and nitrate and cGMP were measured using a kit from
Oxis Research Products (Portland, OR).
Isolated perfused heart and measurement of cardiac function. Experi-
ments were performed using an isovolumic isolated heart preparation and
modiﬁed, as indicated, for mice hearts (23,24). Mice and rats were anesthe-
tized using a mixture of ketamine and xylazine (80 and 10 mg/kg, respec-
tively). After deep anesthesia was achieved, hearts were rapidly excised,
placed in iced saline, and retrogradely perfused at 37°C in a nonrecirculating
mode through the aorta. In mice, the perfusion rate was 2.5 ml/min, and in
rats, the perfusion rate was 12.5 ml/min. Rat and mice hearts were perfused
with modiﬁed Krebs-Henseleit buffer containing 118 mmol/l NaCl, 4.7 mmol/l
KCl, 2.5 mmol/l CaCl2, 1.2 mmol/l MgCl2, 25 mmol/l NaHCO3, 5 mmol/l glucose,
0.4 mmol/l palmitate, 0.4 mmol/l BSA, and 70 mU/l insulin. The perfusate was
equilibrated with a mixture of 95% O2–5% CO2, which maintained perfusate
PO2 600 mmHg. Left ventricular developed pressure (LVDP) and left
ventricular end diastolic pressure were measured using a latex balloon in the
left ventricle. LVDP, heart rate, and coronary perfusion pressure were
monitored continuously on a four-channel Powerlab (AD Instruments, Grand
Junction, CO).
The ischemia/perfusion protocol was as follows: Hemodynamic function
was monitored throughout the protocol. Mice hearts were paced at 420
beats/min with the use of pacing electrodes placed on the right atrium. Rat
hearts were paced at 300 beats/min. Hearts were subjected to 30 min of global
(zero-ﬂow) ischemia and 60 min of reperfusion. Perfusate temperature was
maintained at 37°C at all times during the protocol (i.e., during baseline,
ischemia, and reperfusion). After an equilibration period of 30 min, both
groups of hearts were perfused with modiﬁed Krebs-Henseleit buffer through-
out ischemia and reperfusion.
LDH release, a marker of I/R injury, was measured in the efﬂuents for the
entire 60 min of reperfusion in each heart. The levels of LDH were assayed
using commercially available kits from Sigma-Aldrich. LDH release is ex-
pressed as international unit per gram dry weight of tissue. Caspase-3 activity
was assayed in hearts using reagents provided in the caspase-3 activity kit
from R&D Systems. Brieﬂy, caspase-3 activity is based on cleavage of the
synthetic caspase substrate linked to the color reporter molecule p-nitroani-
line. The amount of hydrolyzed substrate was measured as absorbance at 405
nm. Recombinant human caspase-3 was used as a positive control and to
generate a standard curve. The results are expressed as caspase activity
relative to that of wild-type control animals.
Measurement of ATP. ATP was measured in the neutralized perchloric acid
extracts of hearts according to previously published procedures (23,24).
Determination of AGEs in heart tissue. Heart tissue (25–100 mg wet wt)
was extracted with 10 ml 2:1 chloroform-methanol for 24 h, washed with 10 ml
methanol, and rehydrated in water. Samples were homogenized for 60 s with
a Brinkmann Polytron in 2 ml Chelex-treated PBS (pH 7.4) containing 1 mmol/l
diethylenetriaminepentaacetic acid (DTPA) and protease inhibitor cocktail
(Roche) using one tablet per 10 ml buffer. Homogenates were centrifuged at
1,600 rpm for 20 min using a Sorvall RT 6000D centrifuge. Pellets were washed
three times with water while supernatants were exhaustively dialyzed versus
water. All samples were freeze-dried and stored at 80°C until further
processing. Three milligrams of lyophilized tissue was weighed and placed
into Eppendorf tubes on ice. Samples were solubilized with 100 l PBS and
900 l 1% HCl/Acetone kept at 20°C to remove heme, vortexed, and
centrifuged at 15,000 rpm for 15 min at 4°C. This procedure was repeated
twice. Pellets were then washed with ice-cold 1 mmol/l DTPA, freeze-dried,
and acid hydrolyzed with 6 N HCl for 19 h. AGE analysis (carboxymethyl-
lysine [CML], carboxyethyl-lysine [CEL], fructose-lysine [furosine], and 2-ami-
noadipic acid) was by gas chromatography–mass spectrometry as described
previously (25). Pentosidine was determined by high-performance liquid
chromatography according to Sell et al. (26)
Statistical analysis. Signiﬁcant differences between experimental groups
were detected using ANOVA for unpaired variables. Post hoc comparisons
were performed using Tukey’s or Dunnett’s procedures as indicated. SAS
package software was used in the statistical analyses, and statistical signiﬁ-
cance was ascribed to the data when P  0.05.
RESULTS
Ligand/RAGE axis in the diabetic rat heart. We used
the Biobred/Worcester (BB/W) rat, a model of autoim-
mune type 1 diabetes, to dissect the potential role of RAGE
in the pathogenesis of cardiac dysfunction in diabetes
(14,15) and explored the expression/distribution of RAGE
and its ligands in the diabetic rat heart at baseline, in the
absence of I/R. First, we examined epitopes for CML AGEs
(27,28). CML AGEs are speciﬁc AGE ligands of RAGE (11).
In nondiabetic hearts, CML epitopes were not detected
(Fig. 1A). In contrast, heart tissue retrieved from hyper-
glycemic rats displayed immunoreactive epitopes for CML
AGE (Fig. 1B). In addition to AGEs, although expression
of RAGE ligand S100/calgranulin (12) was not demon-
strated in the hearts of nondiabetic BB/W rats (Fig.
1C), S100/calgranulin epitopes were evident in diabetic
BB/W rat heart (Fig. 1D), in both vascular cells and
cardiomyocytes.
Diabetic BB/W hearts displayed increased RAGE anti-
gen compared with nondiabetic hearts by immunohisto-
chemistry (Fig. 1F and E, respectively) and Western
blotting (P  0.05; Fig. 1M). We examined the hearts to
detect nitrotyrosine epitopes, markers of oxidative injury.
Compared with nondiabetic hearts in which virtually no
nitrotyrosine epitopes were evident, immunohistochemis-
try demonstrated extensive nitrotyrosine epitopes in the
hearts of diabetic BB/W rats (Fig. 1G and H, respectively).
To speciﬁcally localize the cells expressing RAGE in the
diabetic heart, additional studies were performed. Immu-
nohistochemistry using anti-RAGE IgG and anti-CD31
IgG showed that RAGE was expressed in endothelial cells
in the diabetic heart (Fig. 1I and J, respectively). Immu-
nohistochemistry using anti-RAGE IgG and anti–Mac-3
IgG demonstrated that RAGE was expressed in mononu-
clear phagocytes in the diabetic heart (Fig. 1K and L,
respectively). Together, these studies indicated that
RAGE expression was increased in the type 1 diabetic
heart, particularly in endothelial cells and mononuclear
phagocytes.
To test the impact of diabetes on expression of RAGE
and the effects of RAGE blockade, we ﬁrst administered
sRAGE, the extracellular ligand-binding domain of RAGE.
sRAGE was administered to diabetic rats commencing at
the diagnosis of hyperglycemia once daily for 14 days. In
diabetic rats treated with sRAGE, signiﬁcantly lower levels
of RAGE antigen in the heart were observed compared
with vehicle-treated diabetic rats (P  0.05; Fig. 1M). This
observation is consistent with the concept that ligand-
RAGE interaction sustains enhanced expression of RAGE;
once interrupted, cellular expression of RAGE was signif-
icantly lower than that observed in the hearts of vehicle-
treated diabetic rats (29).
Diabetes increases expression of iNOS in the rat
heart: impact of RAGE. To explore the potential impact
of the ligand-RAGE axis in modulating perturbation and
oxidant stress in the heart, we assessed levels of iNOS in
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controls, hearts from diabetic rats displayed increased
iNOS antigen by Western blotting; in the presence of
treatment with sRAGE, levels of iNOS antigen were signif-
icantly lower (P  0.05; Fig. 2A).
In parallel, levels of total nitrite and nitrate and cGMP
were increased in diabetes (P  0.05); in the presence of
sRAGE, levels of total nitrite and nitrate and cGMP in
diabetic hearts were signiﬁcantly lower (P  0.05) and
similar to those observed in nondiabetic age-matched
hearts (Fig. 2B and C, respectively).
Pharmacological blockade of ligand-RAGE axis atten-
uates I/R injury in the diabetic rat heart. We assessed
the potential impact of RAGE on cardiac dysfunction
consequent to I/R in the diabetic rat heart. Two indexes of
cardiac recovery were assessed: LVDP and release of LDH
on reperfusion, the latter an index of myocardial injury.
Diabetic rats displayed a marked decrease in LVDP recov-
ery on reperfusion compared with nondiabetic rats sub-
jected to the same degree of I/R (P  0.05; Fig. 3A). LDH
release was signiﬁcantly higher in diabetic hearts com-
pared with nondiabetic hearts (P  0.05; Fig. 3B). Treat-
A
B
I
Non-Diabetic
RAGE
S100 RAGE C
D
J
E
F
K CD31 RAGE
Diabetic
Diabetic
S100 NT
Mac-3
G
H
L
0
500
1000
1500
2000
2500
3000
3500
ND D/PBS D/sRAGE
R
A
G
E
 
A
n
t
i
g
e
n
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
p<0.05 p<0.05
M
FIG. 1. RAGE, its ligands, and the diabetic rat heart. Hearts of type
1 diabetic BB/W rats were retrieved. Immunostaining of CML/AGEs
(A and B), S100/calgranulin (C and D), RAGE (E and F), and
nitrotyrosine epitopes (G and H) in nondiabetic and diabetic
hearts is shown. RAGE was expressed in endothelial cells and
mononuclear phagocytes, evident using anti-RAGE IgG (I and K),
anti-CD31 IgG (to detect endothelial cells) (J), and anti–Mac-3
IgG (to detect mononuclear phagocyte) (L). Scale bar  100 m.
n  3 rats/group. Western blotting using anti-RAGE IgG was
performed to detect RAGE (M). n  6 rats/group.
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LVDP recovery and signiﬁcantly lower LDH release (P 
0.05; Fig. 3A and B).
Role of RAGE in diabetes-associated cardiac isch-
emic injury: studies in mice. We extended our studies to
murine models, wherein genetic modiﬁcation of RAGE
would complement pharmacological blockade of ligand-
RAGE interaction (sRAGE). We rendered wild-type
BALB/c mice diabetic with STZ and examined the impact
of hyperglycemia on expression of RAGE and its ligands in
the heart. After 14 days of diabetes, we examined levels of
speciﬁc AGE species, CML, CEL, furosine (glycated ly-
sine), and pentosidine in BALB/c mouse hearts (Table 1).
As expected, we found that levels of CML, furosine, and
pentosidine were signiﬁcantly higher in the diabetic
BALB/c mice hearts compared with their nondiabetic
controls (Table 1). In diabetic mice, treatment with sRAGE
prevented the increases in CML and pentosidine levels, but
there was no effect on furosine levels, suggesting an effect
independent of tissue glucose levels (Table 1). Levels of
argpyramidine, CEL, and 2-aminoadipic acid, a marker of
metal catalyzed oxidation, were similar in all of the groups
studied (data not shown). Consistent with increased AGE
ligand levels in the diabetic heart, a signiﬁcant increase in
RAGE antigen by Western blotting was observed in dia-
betic compared with nondiabetic hearts (P  0.05; Fig.
4A). In diabetic mice treated with sRAGE, levels of RAGE
antigen were signiﬁcantly lower (P  0.05) and not differ-
ent from levels observed in euglycemic controls.
To test the impact of diabetes on oxidant stress in the
diabetic heart, we examined levels of iNOS antigen in the
basal state. Compared with nondiabetic mice, signiﬁcant
increases in iNOS antigen were demonstrated in diabetic
BALB/c mouse hearts by Western blotting (P  0.05; Fig.
4B). In the presence of sRAGE, levels of iNOS were
signiﬁcantly lower (P  0.05; Fig. 4B). In parallel, levels of
total nitrite and nitrate and cGMP were increased in the
diabetic versus nondiabetic heart and reduced by sRAGE
(P  0.05; Fig. 4C and D, respectively). When hearts were
subjected to I/R, signiﬁcantly less release of LDH was
demonstrated in hearts retrieved from sRAGE-treated
diabetic mice versus vehicle-treated diabetic mice (P 
0.05; Fig. 4E).
Diabetic homozygous RAGE-KO mice. To speciﬁcally
address the contribution of RAGE, we used homozygous
RAGE-KO mice. RAGE-KO mice or wild-type RAGE-
expressing littermate animals were rendered diabetic
with STZ. We extended the period of diabetes to 12 weeks
to test the impact of RAGE in a chronically diabetic
environment.
We assessed the impact of injury triggered by I/R on
functional recovery of the diabetic heart. LVDP recovery
was signiﬁcantly higher in the diabetic RAGE-KO heart
versus RAGE-expressing littermates (P  0.05; Fig. 5A). In
parallel, levels of LDH measured in the efﬂuent in the
I/R-subjected diabetic animals were signiﬁcantly lower in
the diabetic RAGE-KO versus littermate mice (P  0.05;
Fig. 5B). Levels of ATP in the heart were signiﬁcantly
higher in the diabetic RAGE-KO hearts versus diabetic
controls (P  0.05; Fig. 5C).
Levels of total nitrite and nitrate after I/R were signiﬁ-
cantly lower in diabetic RAGE-KO versus wild-type dia-
betic hearts (2.9  0.9 vs. 6.8  1.1 mol/g tissue; P 
0.05). Furthermore, levels of cGMP in the diabetic heart
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FIG. 2. Diabetes upregulates iNOS in the rat heart: effect of RAGE. Hearts of type 1 BB/W diabetic rats treated with sRAGE or PBS were retrieved,
and Western blotting was performed for detection of iNOS (A) antigen. Levels of total nitrite and nitrate (B) and cGMP (C) were measured. n 
6 rats/group. D, diabetic; ND, nondiabetic.
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FIG. 3. Diabetes enhances cardiac dys-
function and injury in the rat heart: effect
of RAGE. Type 1 BB/W diabetic rats re-
ceived 500 g/day sRAGE or PBS.
Changes in cardiac function, LVDP (A)
and release of LDH (B) in hearts sub-
jected to I/R, are shown. n  6 rats/group.
D, diabetic; ND, nondiabetic.
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hearts (206  66 vs. 616  86 pmol/g tissue; P  0.05).
Based on these ﬁndings in diabetic mice with global
deletion of RAGE, we addressed the speciﬁc roles of
RAGE signaling in endothelial cells or mononuclear
phagocytes on I/R stress in the heart. As endothelial cells
and mononuclear phagocytes were principal RAGE-ex-
pressing cells in the diabetic heart, we used two sets of Tg
mice in which RAGE signal transduction was deﬁcient
based on introduction of a transgene encoding cytoplas-
mic DN RAGE in these cell types.
Tg mice expressing DN RAGE in endothelial cells. To
dissect the role of RAGE signaling in endothelial cell in the
diabetic heart, we generated Tg mice in which DN RAGE
expression was directed to endothelial cells by the PPET
(20). Immunostaining with anti-RAGE IgG revealed that
RAGE expression in the Tg mouse heart was localized to
endothelial cells and not to cardiomyocytes (Fig. 6A).
Mice were rendered diabetic with STZ. Hearts were
excised after 12 weeks of hyperglycemia and subjected to
the isolated perfused heart protocol. On induction of
ischemia or I/R, levels of iNOS antigen in the heart were
signiﬁcantly higher in wild-type mice versus Tg DN PPET
RAGE mice with diabetes (P  0.05; Fig. 6B and C). In
parallel, levels of total nitrite and nitrate were signiﬁcantly
lower in the diabetic Tg DN PPET RAGE mice hearts
versus littermate hearts after I/R (P  0.05; Fig. 6D and E,
respectively).
To assess the impact of DN RAGE in endothelial cells in
I/R injury in the diabetic heart, levels of LDH were
measured in the efﬂuent. LDH release was signiﬁcantly
less in the diabetic Tg DN PPET RAGE hearts versus
wild-type hearts after I/R (P  0.05; Fig. 6F). Levels of ATP
in the heart were signiﬁcantly higher in the diabetic Tg
mice versus wild-type hearts after I/R (Fig. 6G). In con-
trast, LVDP recovery was not signiﬁcantly different be-
tween the diabetic Tg DN PPET RAGE versus diabetic
wild-type littermate hearts after I/R (LVDP recovery on
reperfusion was 39  14% in diabetic Tg DN PPET RAGE
vs. 46  11% in diabetic nontransgenic littermate hearts).
These ﬁndings suggest that the impact of RAGE signaling
in endothelial cells inﬂuences injury but not functional
recovery.
Tg mice expressing DN RAGE in cells of mononuclear
phagocyte lineage. To dissect the potential role of mono-
nuclear phagocyte RAGE signaling in modulating the
response to diabetes and I/R in the heart, we previously
prepared Tg mice expressing DN RAGE selectively in cells
of mononuclear phagocyte lineage using the scavenger
receptor type A promoter (referred to as MSR DN RAGE)
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FIG. 4. Impact of RAGE in I/R in the diabetic
mouse heart: sRAGE. BALB/c mice were ren-
dered diabetic with STZ and murine sRAGE (100
g/day) or vehicle administered. After 2 weeks,
hearts were retrieved and subjected to Western
blotting for detection of RAGE (A) and iNOS
(B) antigens. Levels of total nitrite  nitrate
(C), cGMP (D), and LDH release during reper-
fusion (E) are shown. n  6 mice/group. D,
diabetic; ND, nondiabetic.
TABLE 1
Measurement of AGEs in diabetic BALB/c mice hearts under normoxic perfusion conditions
BALB/c BALB/c-DM BALB/c-DM  sRAGE
AGEs
CML (mol/mol lysine) 12.62  3.39 18.49  1.96* 14.52  1.61
CEL 62.13  9.87 71.46  16.67 70.27  10.91
Furosine (mol/mol lysine) 53.51  7.53 71.08  14.01† 67.57  8.63
Pentosidine (fmol/mg protein) 171.16  27.97 361.40  95.69‡ 166.22  16.25
Data are means  SD. *P  0.05 vs. BALB/c-DM  sRAGE and BALB/c for CML comparison. †P  0.05 vs. BALB/c furosine comparison. ‡P 
0.05 vs. BALB/c-DM  sRAGE and BALB/c for pentosidine comparison.
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DIABETES, VOL. 57, JULY 2008 1945(22). DN RAGE was selectively expressed in mononuclear
phagocyte, and there was no evidence that transgene
expression was extended outside of monocytes/macro-
phages (22).
Consequent to ischemia, signiﬁcantly higher iNOS anti-
gen was expressed in the diabetic wild-type heart versus
Tg DN MSR Tg DN MSR RAGE heart (P  0.05; Fig. 7A).
Similar ﬁndings were observed after I/R (Fig. 7B). In
parallel, diabetic Tg DN MSR Tg DN MSR RAGE mice
hearts displayed signiﬁcantly decreased levels of total
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respectively).
We examined the impact of the DN RAGE transgene in
mononuclear phagocyte on I/R injury in the diabetic heart.
Signiﬁcantly less LDH release was observed after I/R in the
diabetic Tg DN MSR Tg DN MSR RAGE heart versus
diabetic littermate hearts (P  0.05; Fig. 7E). Furthermore,
levels of ATP in the hearts of diabetic Tg mice were
signiﬁcantly higher than those observed in diabetic litter-
mate hearts (P  0.05; Fig. 7F). LVDP recovery on reper-
fusion was similar in both the diabetic Tg and littermate
hearts (LVDP recovery on reperfusion was 47  11% in
diabetic Tg DN MSR RAGE vs. 41  9% in diabetic
nontransgenic littermate hearts).
AGEs in diabetic mice hearts subjected to I/R. We
examined the levels of speciﬁc AGEs, CML, pentosidine,
and furosine (glycated lysine) in diabetic wild-type, RAGE-
KO, Tg DN PPET RAGE, and Tg DN MSR RAGE heart
under baseline conditions and after I/R (Table 2). In the
baseline condition, CML, furosine, and pentosidine levels
were signiﬁcantly lower in diabetic RAGE-KO versus dia-
betic wild-type hearts. In diabetic Tg DN PPET RAGE, and
Tg DN MSR RAGE mice hearts, concentrations of CML,
furosine, and pentosidine were similar to those in diabetic
wild-type hearts (Table 2). CEL, argpyrimidine, and 2-ami-
noadipic acid were similar in all the groups of hearts
studied here (data not shown).
Interestingly, after I/R, CML levels were signiﬁcantly
greater in diabetic WT hearts in comparison with diabetic
RAGE-KO, Tg DN PPET RAGE, and Tg DN MSR RAGE
hearts (Table 2). Furosine was signiﬁcantly reduced in
diabetic RAGE-KO and Tg DN PPET RAGE hearts versus
diabetic wild-type or Tg DN MSR RAGE hearts after I/R.
Pentosidine was signiﬁcantly attenuated in diabetic
RAGE-KO and Tg DN MSR RAGE versus diabetic wild-type
or Tg DN PPET RAGE hearts after I/R. I/R increased CML
by 20% in wild-type diabetic hearts but not in RAGE-KO D
and Tg DN MSR D. These data indicate that CML, pento-
sidine, and furosine are signiﬁcantly reduced in diabetic
RAGE-KO hearts under all perfusion conditions, whereas
in Tg DN PPET RAGE and Tg DN MSR RAGE hearts, only
CML levels are attenuated under all perfusion conditions.
Thus, these data indicate that suppressive effect of DN
RAGE on pentosidine is cell speciﬁc, i.e., expression of DN
RAGE reduced pentosidine in Tg DN MSR but not in Tg
DN PPET mice hearts. Furthermore, data indicate that
most of CML effects appear to be associated with the
endothelial cells, whereas pentosidine effects are pro-
nounced in the mononuclear phagocytes.
Effect of RAGE deletion on apoptosis in diabetic mice
hearts after I/R. To determine whether the RAGE-ligand
interaction mediates cell death in the diabetic heart con-
sequent to I/R, we performed analyses to probe apoptotic
signals, such as cytochrome c release and caspase-3
activation. Caspase-3 activation (Fig. 8A) was signiﬁcantly
reduced in diabetic RAGE RAGE-KO, Tg DN PPET RAGE,
and Tg DN MSR RAGE hearts versus diabetic wild-type
hearts after I/R (P  0.05). Similarly, cytochrome c release
(Fig. 8B) was also reduced in diabetic RAGE RAGE-KO, Tg
DN PPET RAGE, and Tg DN MSR RAGE hearts versus
diabetic wild-type hearts after I/R (P  0.05).
Of note, pharmacological blockade of RAGE, by admin-
istration of sRAGE, or genetic deletion or modulation of
RAGE signaling in endothelial cells or mononuclear
phagocyte had no impact on the levels of glucose in
diabetic rats or mice (Table 3).
DISCUSSION
RAGE and NOS. In diabetes, cells within the vascular
milieu produce NO and superoxide, at least in part, via the
direct action of glucose itself and by its downstream
effector species, such as AGEs (30). The generation of a
potent longer-lived oxidant peroxynitrite, due to interac-
tion of NO and superoxide, has deleterious consequences,
such as inhibition of mitochondrial electron transport,
oxidation of sulfhydryl groups in proteins, initiation of
lipid peroxidation, nitration of amino acids (31), and
uncoupling of endothelial NO synthase by peroxynitrite
leading to ampliﬁcation of oxidant stress (32). Peroxyni-
trite induces formation of CML-modiﬁed adducts by cleav-
age of Amadori products and the generation of glucosone
and glyoxal from glucose, thus providing a “refueling
mechanism” by which diabetes-mediated generation of
CML leads to oxidant stress and, in part, regeneration of
CML epitopes (33).
It is likely that inhibition of the synthesis of NO by iNOS
plays an important role. Our results are consistent with
previous studies of acute ischemia and reperfusion in
which administration of semi-selective inhibitors of iNOS
or iNOS-null mice enhanced cardiac performance and/or
reduced myocardial infarct size (34–37). Previous studies
showed that iNOS played critical roles in diabetes and I/R
in the heart, because iNOS-null mice displayed protection
from the adverse effect of this injury, especially in diabetes
(38). Our ﬁndings deﬁnitively link RAGE and RAGE sig-
naling in endothelial cells and mononuclear phagocyte to
generation of NO and pathogenic oxidant stress species in
the diabetic heart. The impact of DN RAGE in both
TABLE 2
Measurement of AGEs in diabetic RAGE KO mice hearts under baseline normoxic and I/R conditions
Wild-type-DM RAGE-KO-D Tg DN PPET-D Tg DN MSR-D
CML B 34.88  4.46 21.73  1.25* 31.92  4.67 39.44  7.87
I/R 41.83  5.48† 24.63  3.44 22.73  1.25 27.86  4.88
Pentosidine B 191.16  27.97 137.67  20.61‡ 197.37  38.02 209  49.57
I/R 190.65  44.83 105.66  20.55§ 180.46  34.71 116.52  29.07§
Furosine B 135.51  7.79 98.07  2.40¶ 126.76  9.31 121.58  11.32
I/R 123.30  4.76 101.81  8.05 107.87  5.09 129.77  9.94
Data are means  SD. *P  0.05 RAGE-KO-D vs. all other groups for CML comparison. †P  0.05 wild-type-DM vs. all other groups for CML
comparison. ‡P  0.05 RAGE-KO-D vs. all other groups for pentosidine comparison. §P  0.05 RAGE-KO-D, DNMSR vs. all other groups for
pentosidine comparison. ¶P  0.05 RAGE-KO-D vs. all other groups for furosine comparison. P  0.05 RAGE-KO-D, DNPPET vs. all other
groups for furosine comparison. CML and furosine are expressed as mol/mol lysine, whereas pentosidine is expressed as fmol/mg protein.
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explained, in part, by the fundamental interplay and cross-
talk between the molecular and biochemical conse-
quences of endothelial cells and mononuclear phagocyte
activation.
RAGE and myocardial energy metabolism. Our studies
indicate that RAGE inﬂuenced myocardial energy metab-
olism. At the end of global ischemia, levels of cardiac ATP
were reduced signiﬁcantly in all hearts; however, higher
levels of ATP were observed in diabetic RAGE signaling
mutant Tg mice or RAGE-KO mice compared with diabetic
littermates. In global ischemia, ATP production results
primarily from anaerobic glycolysis. Nitrosylation of
GAPDH is a potential mechanism by which NO is likely to
mediate inhibition of anaerobic glycolysis during global
ischemia (39,40). Recent ﬁndings from our laboratory
demonstrated reduced myocardial GAPDH activity and
levels of glyceraldehyde-3-phosphate at the end of the
ischemic period and normalization of these changes by
inhibition of iNOS (41). Higher iNOS expression and NO
production have been shown, in part, to impair glycolysis
and to reduce ATP levels in ischemic hearts. Our data
demonstrating reduced iNOS expression, total nitrite and
nitrate levels, and improved ATP levels in RAGE-inhibited
ischemic hearts are consistent, in part, with RAGE block-
ade improving anaerobic glycolysis.
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the impact of RAGE in generation of iNOS and nitrite and
nitrate and cGMP, especially consequent to I/R. In rats
rendered diabetic with STZ, the impact of diabetes and
NOS in the heart was demonstrated by the beneﬁcial
effects of L-NAME (L-N
G-nitro-L-arginine methyl ester) in
improvement of ventricular performance (42). Our ﬁnd-
ings extend these concepts to link RAGE in the diabetic rat
heart and RAGE signaling in either mononuclear phago-
cyte or endothelial cells in the diabetic mouse heart to
iNOS expression and enhanced injury in I/R, as measured
by LDH release. The ﬁnding that levels of ATP are restored
in diabetic RAGE-KO mice or Tg mice expressing signal-
ing-deﬁcient mutant RAGE mice in I/R provides a direct
link between oxidant stress, NOS, and energy metabolism.
Our studies in diabetic rats deﬁnitively showed that
pharmacological blockade of RAGE protected the isolated
perfused heart from damage and dysfunction, the latter
measured by LVDP. In parallel, release of LDH was atten-
uated by RAGE blockade. In mice, pharmacological block-
ade of RAGE or genetic manipulation (RAGE-KO)
attenuated the release of LDH and improved LVDP and
ATP recovery. Although RAGE signaling signiﬁcantly af-
fected I/R injury and iNOS expression in diabetes, there
was no effect on functional recovery in DN RAGE Tg mice.
However, studies in mice globally deﬁcient in RAGE
displayed improvement in functional recovery consequent
to I/R. These ﬁndings suggest a number of possibilities.
First, it is plausible that distinct cell types expressing basal
levels of RAGE, such as cardiomyocytes or T lymphocytes,
may contribute to the ﬁndings on functional recovery
observed in RAGE-KO mice. Second, the interplay be-
tween inﬂammatory cell and endothelial RAGE signaling
may be a critical component of the biochemical and
molecular events that, taken together, augur impairment in
functional recovery in the I/R diabetic heart. Thus, future
studies must address distinct signal transduction mutants
of RAGE to broadly probe the potential effects of RAGE
signaling in alternative cell types.
These studies support that the ligands of RAGE, upregu-
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TABLE 3
Glucose levels
Serum glucose (mg/dl)
Type 1 BB/W rats
Control/() diabetes 70.3  10.5
Diabetes/PBS 353.4  53.6*
Diabetes/sRAGE 365.0  87.2*
BALB/c mice
Control/() diabetes 74.9  11.9
Diabetes/PBS 312.8  40.2*
Diabetes/sRAGE 306.3  26.8*
Homozygous RAGE-KO mice and
littermate controls
Wild-type () diabetes 72  10.2
Wild-type () diabetes 437  56*
RAGE-KO () diabetes 86  9.4
RAGE-KO () diabetes 388  99*
Transgenic PPET DN RAGE mice
Wild-type () diabetes 66.9  8.5
Wild-type () diabetes 300.2  13.3*
Tg DN PPET RAGE () diabetes 79.1  5.6
Tg DN PPET RAGE () diabetes 318.4  44.6*
Transgenic MSR DN RAGE mice
Wild-type () diabetes 69.4  7.4
Wild-type () diabetes 309.7  18.7*
Tg DN MSR RAGE () diabetes 73.7  9.4
Tg DN MSR RAGE () diabetes 331.2  45.6*
Data are means  SD. Glucose levels were determined in BB/W rats,
BALB/c, homozygous RAGE-KO, and DN RAGE transgenic mice at
the time of death. *P  0.05 vs. comparing diabetes with the absence
of diabetes in respective controls.
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ducing the long-term impact of hyperglycemia. Certainly,
basally increased levels of AGEs in the hyperglycemic
heart may set the stage for ampliﬁcation of injury, via
RAGE, on superimposed I/R. Distinct RAGE ligands, such
as S100/calgranulins may also play important roles in the
I/R heart. In the isolated perfused heart, ischemic rat
hearts release S100b (43). Studies have linked S100b to
maladaptive remodeling after experimental infarction in
mouse models (44). Our recent studies, performed in the
absence of diabetes, demonstrated that a primary stimulus
to release and recruitment of the RAGE axis ensues
primarily from the ischemic insult (45). Ischemic insult
induces increases in AGE-RAGE expression and leads to
increased injury (45).
In this study, we show that diabetes increases AGEs
such as CML, pentosidine, and furosine under baseline and
I/R conditions. Levels of CML, pentosidine, and furosine
were signiﬁcantly reduced in diabetic RAGE KO mice
hearts. Targeted expression of DN RAGE in endothelial
cells or mononuclear phagocytes attenuated CML accumu-
lation in these diabetic hearts under all perfusion condi-
tions, whereas pentosidine was attenuated in diabetic Tg
DN MSR RAGE after I/R and furosine was attenuated in
diabetic Tg DN PEET RAGE hearts after I/R. These data
indicate that CML is a key AGE that is linked to RAGE-
dependent injury after I/R in diabetic hearts. Taken to-
gether, our ﬁndings highlight potential roles for the RAGE
axis at multiple stages of injury in the diabetic, ischemic
heart.
We observed that in diabetic RAGE KO, Tg DN PPET
RAGE, and Tg DN MSR RAGE mice hearts, protection
from injury due to I/R was also associated with reductions
in caspase-3 activation and cytochrome c release. These
experiments are consistent with our and other earlier
studies that have linked protection of ischemic hearts to
reduced apoptosis in mice models of I/R including in the
setting of diabetes (46–50)
In conclusion, these studies deﬁnitively link RAGE to
myocardial ischemic injury and dysfunction in the diabetic
heart. We propose that blockade of RAGE may provide a
novel means to exert cardioprotection in the vulnerable
diabetic heart, particularly consequent to I/R injury.
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